Edico Genome

What Edico Genome does

Edico Genome, founded in 2013 in San Diego, developed the DRAGEN (Dynamic Read Analysis for GENomics) bioinformatics platform for secondary analysis of next-generation sequencing (NGS) data. The platform replaces up to 30 open-source tools with a single validated pipeline supporting germline, somatic, RNA, and methylation analysis, and is differentiated by hardware-accelerated processing (FPGA), pangenome-based multi-genome mapping, and lossless ORA compression. Edico Genome was acquired by Illumina and now operates as a wholly-owned subsidiary; DRAGEN is distributed through Illumina's global enterprise sales organization with deployment options including on-premises servers, cloud, and onboard integration with Illumina sequencers (NovaSeq X, NextSeq 1000/2000, MiSeq i100).

The company serves a horizontal customer base spanning life science researchers, clinical laboratories, pharmaceutical and biotech firms, and oncology research programs, with named enterprise references including UK Biobank, Cardio-CARE, and Basepaws. DRAGEN's value proposition is anchored in independently verified accuracy (99.90% on the PrecisionFDA Truth Challenge v2), world-record processing speeds (~34 minutes for a 40x genome), and material storage cost reductions (80% via built-in lossless compression). Recent product releases (v4.3 in 2024, v4.4 in 2025) have expanded DRAGEN into clinical oncology (Heme WGS, Solid WGS tumor-normal, Minimal Residual Disease), population-scale variant aggregation (Iterative gVCF Genotyper), and pharmacogenomics (PGx pipeline).

Pricing is not publicly disclosed; the primary call-to-action is 'Request a demo,' indicating a consultative enterprise sales motion. Pre-acquisition, the company raised approximately $32 million across seed (2013, EvoNexus), Series A (2014, $10M led by Qualcomm Ventures), and Series B (2017, $22M led by Dell Technologies Capital). Since the Illumina acquisition, Edico Genome has not operated as an independent commercial entity, and DRAGEN-specific revenue is not separately disclosed in Illumina's reporting.

Name

Edico Genome

Legal name

Edico Genome

Website

https://edicogenome.com

Company type

Private

Founded year

2013

Operating status

Acquired

Headcount range

11–50 employees

Short description

Edico Genome, now an Illumina subsidiary, develops the DRAGEN bioinformatics platform for NGS secondary analysis, serving research, clinical, pharma, and oncology customers with hardware-accelerated variant calling, population-scale pipelines, and onboard integration with Illumina sequencers.

Ownership category

akta.pro rank

Product category

Bioinformatics Software

NAICS

Software Publishers (5132)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)

akta.pro secondary industry

Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA)

Keywords

• NGS data analysis
• Bioinformatics software
• Genomic sequencing
• Variant calling
• Secondary analysis

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Infrastructure, Operations

Distribution channels4 records

Marketing channels5 records

Core offering

Edico Genome developed DRAGEN (Dynamic Read Analysis for GENomics), a hardware-accelerated bioinformatics platform that performs secondary analysis of next-generation sequencing (NGS) data. The platform replaces up to 30 open-source tools with a single solution supporting whole-genome, exome, methylome, and transcriptome analysis, deployable on-premises, in the cloud, or directly onboard Illumina sequencers.

Product overview

Edico Genome, now part of Illumina, developed DRAGEN (Dynamic Read Analysis for GENomics) secondary analysis software — a comprehensive bioinformatics platform for NGS data processing. The core product is DRAGEN Secondary Analysis (formerly DRAGEN Bio-IT Platform), which consolidates up to 30 open-source tools into a single solution. The platform includes specialized pipelines for Germline (whole-genome and enrichment), Somatic (whole-genome, enrichment, tumor-only, and tumor-normal), RNA, and Methylation analysis. Additional modules include the Iterative gVCF Genotyper (IGG) for population-scale variant discovery, the PGx pipeline for pharmacogenomics, and ORA compression for efficient data storage. The software is deployable via on-premises server, cloud-based, or directly onboard Illumina sequencers including NovaSeq X Series, NextSeq 1000/2000, and MiSeq i100 Series.

Differentiator

Problem solved

Functional benefit

Brands

• DRAGEN Bio-IT Platform: Former name of the bioinformatics pipeline product developed by Edico Genome for secondary analysis of NGS data. Renamed to DRAGEN secondary analysis after acquisition by Illumina.

Products and services

• DRAGEN Secondary Analysis A comprehensive bioinformatics software suite for processing next-generation sequencing data, providing accurate and efficient secondary analysis including variant calling, alignment, and genomic data processing for whole genomes, exomes, methylomes, and transcriptomes. Targeted at genomic researchers, clinical laboratories, and pharmaceutical companies.
• DRAGEN Germline Pipeline Germline variant calling pipeline supporting both whole-genome and enrichment (targeted) analysis workflows for identifying inherited genetic variants in research and clinical genomics.
• DRAGEN Somatic Pipeline Somatic variant calling pipeline supporting whole-genome and enrichment analysis with tumor-only and tumor-normal comparison workflows for oncology research and precision medicine applications.
• DRAGEN RNA Pipeline Transcriptome analysis pipeline for RNA sequencing data processing and differential expression analysis, used in gene expression research studies.
• DRAGEN Methylation Pipeline Epigenomic analysis pipeline for processing methylome data from bisulfite sequencing experiments, enabling epigenetic studies.
• DRAGEN Iterative gVCF Genotyper (IGG) Population-scale variant discovery solution enabling fast aggregation and genotyping of small germline variants across large cohorts, with incremental analysis so new sample batches can be added without reprocessing the entire dataset. Used for biobank-scale and population genomics research.
• DRAGEN PGx Pipeline Pharmacogenomics pipeline enabling genotyping of 20 genes related to drug metabolism to support drug development research and pharmacogenomic studies.

Quantifiable outcome

• 99.90% accuracy score on Precision FDA Truth Challenge v2 benchmark data
• +5 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature9 records

Partnerships

One partnership is on record.

• IlluminacoreOEM/ Whitelabel/ Licensing PartnerEdico Genome developed DRAGEN technology which was acquired by Illumina. Illumina now owns, markets, and distributes the DRAGEN secondary analysis platform as part of its bioinformatics portfolio. The technology is available through Illumina's sales channels, integrated onboard Illumina sequencers, and delivered via Illumina's cloud and on-premises deployment options.

Recent moves6 records

Expansion highlights5 records

Direct peers

• DNAnexus: DNAnexus provides a cloud genomics platform hosting pipelines and tertiary analysis for clinical and translational customers. It directly competes with cloud-deployed DRAGEN and is used by similar pharma, clinical, and large-scale consortia (NIH, Genomics England-adjacent projects).
• Partek (now part of Illumina): Partek Flow and Partek EpiCenter provide NGS and multi-omics analysis software used by the same life-science researcher and translational genomics customers as DRAGEN. Recently acquired by Illumina, it sits alongside DRAGEN in Illumina's informatics portfolio — most analogous in target market and product category.
• Velsera (formerly Seven Bridges Genomics): Velsera operates a cloud-based genomics analysis platform (Seven Bridges Platform, Cancer Genomics Cloud) supporting secondary and tertiary analysis workflows. It competes directly with DRAGEN for population-scale and clinical genomics deployments, particularly via cloud distribution rather than on-prem hardware.
• Sentieon: Sentieon provides production-grade NGS secondary analysis pipelines (DNAscope, TNseq, Haplotyper) focused on clinical-grade accuracy and speed. It is the most direct head-to-head competitor to DRAGEN for germline/somatic variant calling and shares the same customer base of clinical labs and sequencing centers.
• Golden Helix: Golden Helix (VarSeq + SVS) offers secondary and tertiary NGS analysis with a focus on annotating and filtering variants for clinical reporting. It overlaps with DRAGEN downstream — used by similar clinical labs, often layering on top of pipeline outputs to make medical-grade variant calls.

Emerging players

• Fabric Genomics: Fabric Genomics (acquired by Illumina) provides AI-powered clinical genome interpretation. It sits downstream of DRAGEN and represents an emerging interpretive layer rather than a direct pipeline competitor, but competes for the same clinical genomics customer wallet.
• SOPHiA GENETICS: SOPHiA DDM is an AI-driven multimodal genomics analysis platform targeting clinical diagnostics, particularly oncology and rare disease. It overlaps with DRAGEN at the secondary/tertiary analysis boundary but focuses on hospital lab deployment with CE-IVD/FDA pathways — a different distribution and clinical thesis.

Broad incumbents

• QIAGEN Digital Insights (CLC bio, QIAseq): QIAGEN's CLC Genomics Workbench and QIAseq/HSP-derived pipeline ecosystem serve the same primary bioinformatics customers with a broader wet-lab + dry-lab portfolio. It is a broader incumbent — overlapping in NGS analysis but extending into instruments, reagents, and interpretation that DRAGEN does not cover.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/EdicoGenome
• Facebookfacebook.com/edicogenome
• LinkedInlinkedin.com/company/edico-genome

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds3 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Edico Genome